Residual Risk of Relapse: a Systematic Review and a Consensus Project on Unmet needs for HER2-positive non Metastatic Breast Cancer Patients

Federica Miglietta(University of Padua), P. Conte(Istituto Oncologico Veneto), G. Griguolo(Istituto Oncologico Veneto), G. Pappagallo(Sacred Heart Hospital), F. Girardi(Istituto Oncologico Veneto), V. Guarneri(Istituto Oncologico Veneto), P. Pronzato(Accademia Nazionale dei Lincei)
European Journal of Cancer
November 1, 2022
10.1016/s0959-8049(22)01504-0
Cited by 1

Related Papers

Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
|Cells|2021|227
Evolution of HER2-low expression from primary to recurrent breast cancer
|npj Breast Cancer|2021|226
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
|Cancer Treatment Reviews|2016|128
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
|Cancers|2019|115
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment
|npj Breast Cancer|2022|100